Laboratoire de biométrie et biologie évolutive, CNRS, UMR 5558, Équipe EME, université de Claude Bernard Lyon 1, 8, rue Guillaume Paradin, Bât B, 69008 Lyon, France.
Laboratoire de biométrie et biologie évolutive, CNRS, UMR 5558, Équipe EME, université de Claude Bernard Lyon 1, 8, rue Guillaume Paradin, Bât B, 69008 Lyon, France; Department of Clinical Epdiemiology, Clinical Investigation Centre CIC-Inserm 1407, EPICIME, Hospices Civils de Lyon, 69500 Bron, France.
Therapie. 2022 Jul-Aug;77(4):445-452. doi: 10.1016/j.therap.2021.12.013. Epub 2021 Dec 23.
To identify the 10 drugs most frequently administered to children in liquid dosage forms which are eligible for replacement with suitable authorized solid dosage forms and to assess the expected economic impact of this substitution.
The health record data from 312,152 oral drug administrations were analyzed. Ten drugs were selected according to their frequency of administration in liquid dosage forms, the availability of solid form alternatives, and the suitability of these alternatives for the children receiving the corresponding liquid forms. Potential hospital cost savings of the suggested substitutions were calculated.
The 10 drugs identified as most frequently administered and for which suitable solid forms were available were: paracetamol, cyamemazine, valproic acid, clonazepam, furosemide, prazepam, hydroxyzine, alfacalcidol, amitriptyline, and levetiracetam. Thirty-four point six of the administrations of these drugs in liquid dosage forms could be delivered using suitable solid dosage forms without additional cost.
Opportunities exist for substituting liquid dosage forms with market-available solid dosage forms suitable in size and dosage for the pediatric population.
确定最常用于儿童液体剂型的 10 种药物，这些药物有资格用合适的已授权固体剂型替代，并评估这种替代的预期经济影响。
对 312152 例口服药物给药的健康记录数据进行了分析。根据液体剂型给药的频率、固体剂型替代品的可用性以及这些替代品对接受相应液体剂型的儿童的适用性，选择了 10 种药物。计算了建议替代的潜在医院成本节约。
确定了最常给药且有合适固体剂型的 10 种药物：对乙酰氨基酚、环喷他嗪、丙戊酸、氯硝西泮、呋塞米、地西泮、羟嗪、阿法骨化醇、阿米替林和左乙拉西坦。这些药物的 34.6%的液体剂型给药可以使用合适的固体剂型替代，而无需额外费用。
存在用市场上已有的适合儿科人群的大小和剂量的固体剂型替代液体剂型的机会。
